Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. appeals court upholds ruling that canceled Teva Copaxone patents

A U.S. appeals court upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd. on the blockbuster multiple sclerosis drug Copaxone.

Read More »

Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

Read More »

AbbVie settles Humira patent disputes with Sandoz

AbbVie Inc. settled all patent disputes with Novartis AG, granting the Swiss drugmaker a non-exclusive license to manufacture and sell a copycat version of the blockbuster drug Humira.

Read More »

Jury clears J&J of liability in NJ talc cancer case

A New Jersey jury cleared J&J of liability in a case involving a woman who alleged that the company’s talc-based products, including baby powder, contain asbestos and caused her cancer.

Read More »

Pfizer settles New York probe into ‘deceptive’ copay coupons

Pfizer Inc. settled charges by New York’s attorney general that the company misled consumers in a drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out.

Read More »

Walgreens revenue hit by weakness in personal care products, OTC drugs

Walgreens Boots Alliance Inc. came up short of analysts’ estimates for quarterly revenue, as sales of personal-care products and over-the-counter drugs fell both in the U.S. drugstore operator’s home market and UK-based Boots chain.

Read More »

Bristol-Myers to invest in Compugen, collaborate in clinical trials

Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.

Read More »

U.S. FDA panel backs Celltrion biosimilar

An advisory panel to the U.S. Food and Drug Administration voted unanimously in favor of Celltrion Pharm Inc.’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan.

Read More »

CVS, Aetna win U.S. approval for merger

Pharmacy chain CVS Health Corp. won U.S. antitrust approval for the $69 billion acquisition of health insurer Aetna Inc., the Justice Department said.

Read More »

FDA staff says AcelRx opioid painkiller is not better than rivals

AcelRx Pharmaceuticals Inc.’s opioid painkiller offers no apparent advantage to currently available therapies, staff reviewers of the U.S. Food and Administration said.

Read More »

Mental health crisis could cost the world $16 trillion by 2030

Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.

Read More »

UK clinical trials fall as Brexit clouds drug approval process

The number of new clinical trials started in Britain during 2017 was 25 percent lower than the average for 2009-2016, as anxiety about Brexit’s impact on future medicines regulation made companies hesitate about running studies in the country.

Read More »

FDA staff raises safety issues over Trevena opioid injection

Trevena Inc.’s opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. FDA said, sending the drugmaker’s shares down 66 percent.

Read More »

J&J’s Stelara succeeds in chronic bowel disease study

Johnson & Johnson said the company’s blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.

Read More »

Affimed puts on hold cancer drug trial after patient death

Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.

Read More »

Bausch Health’s plaque psoriasis lotion gets tentative FDA approval

Bausch Health, formerly Valeant Pharmaceuticals, received tentative U.S. approval to market the plaque psoriasis lotion Bryhali.

Read More »

Akcea Therapeutics genetic disease treatment gets FDA approval

The U.S. Food and Drug Administration approved Akcea Therapeutics’ rare genetic disease drug Tegsedi, which was developed along with Ionis Pharmaceuticals.

Read More »

EMA committee recommends restrictions on fluoroquinolone, quinolone antibiotics

The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.

Read More »

Taking vitamin D supplements may not improve bone health

Vitamin D supplementation may not improve bone density or prevent fractures and falls in adults, a large new analysis suggests.

Read More »

U.S. FDA expands approval of Roche hemophilia drug

U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom